Case Series
Surgical Outcomes in Macular Telangiectasia Type 2-Related Macular Holes: A Report on Four Patients
Table 1
Summary table of patient characteristics, surgical methods, and outcomes of patients with FTMH associated with MacTel Type 2.
| | Case 1 OD | Case 1 OS | Case 2 OD | Case 3 OS | Case 4 OD |
| Age (years) | 62 | 62 | 71 | 65 | 57 | Gender | Female | Female | Male | Female | Female | Preoperative BCVA | 20/80 | 20/80 | 20/50 | 20/200 | 20/60 | Time from symptom onset to surgery | 1 month | 3 months | 4 months | 9 months | Unknown | Macular hole size (μm) | | | | | | Diameter | 410 | 246 | 225 | 184 | 493 | Maximum height | 426 | 424 | 340 | 403 | 309 | Posterior vitreous detachment | Yes | Yes | No | No | No | Surgical procedure | PPV, ICG-assisted ILM peeling, cataract surgery done at the time of PPV | PPV, ICG-assisted ILM peeling, cataract surgery done at the time of PPV | PPV, ICG-assisted ILM peeling | PPV, ICG-assisted ILM peeling | PPV, ICG-assisted ILM peeling, cataract surgery done 1 month prior to PPV | Tamponading agent | 30% SF6 | 30% SF6 | 30% SF6 | 30% SF6 | 15% C3F8 | Positioning, duration | Prone, 1 week | Prone, 1 week | Prone, 1 week | Prone, 1 week | Prone, 1 week | Anatomical hole closure | Closed hole | Closed hole | Closed hole | Closed hole | Not closed | EZ and ELM integrity on most recent OCT | Yes | Yes | Yes | Yes | No | BCVA at last follow-up | 20/25 | 20/20 | 20/20-1 | 20/40-1 | 20/60 | Length of follow-up | 26 months | 37 months | 21 months | 35 months | 22 months |
|
|
PPV: pars plana vitrectomy; ILM: internal limiting membrane; ICG: indocyanine green; EZ: ellipsoid zone; ELM: external limiting membrane; BCVA: best corrected visual acuity; SF6: sulfur hexafluoride; C3F8: perfluoropropane.
|